The increased PD‐L1 expression in 4T1 cells can inhibit T cell responses and facilitate immune evasion of tumor cells,[42] which suggests that CuP/Er can be combined with ICB to reinvigorate T cell‐mediated immune response for effective cancer immunotherapy. The gene discussed is CD274; the disease is cancer.